| Viatris is a global healthcare company. Co.'s portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas. Co. has four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Key products sold by the Developed Markets segment include Lyrica®, Lipitor®, Creon®, Influvac®, Wixela Inhub, and the EpiPen® Auto-Injector. Key products within the Greater China segment include Lipitor®, Norvasc®, and Viagra®. Key products within the JANZ segment include AMITIZA®, Lipacreon®, Lyrica®, Norvasc®, and Effexor®. Among Co.'s products sold in the Emerging Markets segment are Lipitor®, Lyrica®, Norvasc®, Celebrex®, and anti-retrovirals. We show 6 historical shares outstanding datapoints in our VTRS shares outstanding history coverage, used to compute VTRS market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing VTRS market cap history over the course of time is important for investors
interested in comparing VTRS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of VTRS versus a peer is one thing; comparing
VTRS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like VTRS can fluctuate over the course of history.
With this page we aim to empower investors researching VTRS by allowing them to research the VTRS market cap history.